BioStem Technologies has appointed Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee. Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies on initial and secondary public offerings, business combinations, risk assessment and regulatory compliance. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules.
This appointment comes at a pivotal time for BioStem as the company expands beyond chronic wound care and plans to raise its profile in public markets in 2026. Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that Ungrodt's twenty-nine years of life sciences accounting experience at Ernst & Young, along with her track record advising more than thirty IPOs and deep regulatory expertise, will strengthen board governance during this growth phase. As Audit Committee Chair, Ungrodt will oversee the company's financial reporting, internal controls and risk management practices.
BioStem is an emerging leader in placental and umbilical cord-derived tissue products used by clinicians across various medical specialties. The company's proprietary allograft portfolio is derived from donated birth tissue using processes designed to preserve the tissue's natural properties. BioStem continues to conduct research to expand scientific understanding of placental-derived tissue products and bring new products to market. The company's quality management system has been accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes.
Ungrodt's prior experience includes serving as Chair of the Audit Committee for Feeding San Diego, where she provided accounting, budgeting and risk assessment guidance for over a decade. She is also an Advisory Board Member for Life Science Cares. During her tenure at EY, Ungrodt served more than 70 companies across the Life Sciences sector. Ungrodt holds a BS in Accounting from San Diego State University and is a Certified Public Accountant and member of the American Institute of Public Accountants and the California Society of CPAs.
Ungrodt stated that she is excited to join BioStem's board as the company demonstrates strong momentum in the chronic wound market and expands into acute applications of its technologies. She noted that these technologies have potential to improve patient outcomes as the company continues to scale and innovate. Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem's chief financial officer in August 2025 after serving on the board for three years. For more information about BioStem Technologies, visit https://www.biostemtechnologies.com.
